Cargando…
Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527459/ https://www.ncbi.nlm.nih.gov/pubmed/37759784 http://dx.doi.org/10.3390/biom13091384 |
_version_ | 1785111152831758336 |
---|---|
author | Bianconi, Vanessa Cafaro, Giacomo Mannarino, Massimo Raffaele Perricone, Carlo Cosentini, Elena Bistoni, Onelia Paltriccia, Rita Lombardini, Rita Gerli, Roberto Pirro, Matteo Bartoloni, Elena |
author_facet | Bianconi, Vanessa Cafaro, Giacomo Mannarino, Massimo Raffaele Perricone, Carlo Cosentini, Elena Bistoni, Onelia Paltriccia, Rita Lombardini, Rita Gerli, Roberto Pirro, Matteo Bartoloni, Elena |
author_sort | Bianconi, Vanessa |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCSK9, measures of immune–inflammatory status and markers of atherosclerosis in 52 consecutive patients with primary Sjögren’s syndrome (pSS) in comparison to healthy controls (HCs). Median plasma PCSK9 levels were significantly higher in pSS patients versus HCs (162 (79–255) vs. 53 (39–99) ng/mL). Significantly higher prevalence of subclinical atherosclerosis and lower of dyslipidaemia (61% vs. 85%, p = 0.042) characterized pSS patients versus HCs. In pSS, no significant correlation emerged between PCSK9 and disease activity, atherosclerosis and lipid levels. In HCs, PCSK9 significantly correlated with lipid levels and atherosclerosis. Interestingly, significantly higher PCSK9 levels were found in HCs with high-to-very-high as compared to low-to-moderate CV risk (p = 0.018) while a non-significant trend towards higher PCSK9 levels was detected in pSS patients with low-to-moderate as compared to high-to-very-high CV risk (p = 0.060). This is the first demonstration that pSS patients, despite lower prevalence of dyslipidaemia and higher CV risk profile, are characterized by a 3-fold increase in PCSK9 levels in comparison to HCs. As PCSK9 does not correlate with measures of CV risk, its role in CV morbidity in pSS needs further investigation. |
format | Online Article Text |
id | pubmed-10527459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105274592023-09-28 Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome Bianconi, Vanessa Cafaro, Giacomo Mannarino, Massimo Raffaele Perricone, Carlo Cosentini, Elena Bistoni, Onelia Paltriccia, Rita Lombardini, Rita Gerli, Roberto Pirro, Matteo Bartoloni, Elena Biomolecules Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCSK9, measures of immune–inflammatory status and markers of atherosclerosis in 52 consecutive patients with primary Sjögren’s syndrome (pSS) in comparison to healthy controls (HCs). Median plasma PCSK9 levels were significantly higher in pSS patients versus HCs (162 (79–255) vs. 53 (39–99) ng/mL). Significantly higher prevalence of subclinical atherosclerosis and lower of dyslipidaemia (61% vs. 85%, p = 0.042) characterized pSS patients versus HCs. In pSS, no significant correlation emerged between PCSK9 and disease activity, atherosclerosis and lipid levels. In HCs, PCSK9 significantly correlated with lipid levels and atherosclerosis. Interestingly, significantly higher PCSK9 levels were found in HCs with high-to-very-high as compared to low-to-moderate CV risk (p = 0.018) while a non-significant trend towards higher PCSK9 levels was detected in pSS patients with low-to-moderate as compared to high-to-very-high CV risk (p = 0.060). This is the first demonstration that pSS patients, despite lower prevalence of dyslipidaemia and higher CV risk profile, are characterized by a 3-fold increase in PCSK9 levels in comparison to HCs. As PCSK9 does not correlate with measures of CV risk, its role in CV morbidity in pSS needs further investigation. MDPI 2023-09-12 /pmc/articles/PMC10527459/ /pubmed/37759784 http://dx.doi.org/10.3390/biom13091384 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bianconi, Vanessa Cafaro, Giacomo Mannarino, Massimo Raffaele Perricone, Carlo Cosentini, Elena Bistoni, Onelia Paltriccia, Rita Lombardini, Rita Gerli, Roberto Pirro, Matteo Bartoloni, Elena Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title | Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title_full | Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title_fullStr | Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title_full_unstemmed | Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title_short | Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome |
title_sort | exploring the link between plasma levels of pcsk9, immune dysregulation and atherosclerosis in patients with primary sjögren’s syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527459/ https://www.ncbi.nlm.nih.gov/pubmed/37759784 http://dx.doi.org/10.3390/biom13091384 |
work_keys_str_mv | AT bianconivanessa exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT cafarogiacomo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT mannarinomassimoraffaele exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT perriconecarlo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT cosentinielena exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT bistonionelia exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT paltricciarita exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT lombardinirita exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT gerliroberto exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT pirromatteo exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome AT bartolonielena exploringthelinkbetweenplasmalevelsofpcsk9immunedysregulationandatherosclerosisinpatientswithprimarysjogrenssyndrome |